Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
OCULAR THERAPEUTIX, INC (OCUL)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/07/2023 |
8-K
| Quarterly results |
| 05/08/2023 |
8-K
| Quarterly results |
| 03/06/2023 |
8-K
| Quarterly results |
| 11/07/2022 |
8-K
| Quarterly results |
| 08/08/2022 |
8-K
| Quarterly results |
| 05/09/2022 |
8-K
| Quarterly results |
| 11/08/2021 |
8-K
| Quarterly results |
| 08/09/2021 |
8-K
| Quarterly results |
| 05/05/2021 |
8-K
| Quarterly results |
| 03/11/2021 |
8-K
| Quarterly results |
| 11/05/2020 |
8-K
| Quarterly results |
| 08/07/2020 |
8-K
| Quarterly results |
| 05/08/2020 |
8-K
| Quarterly results |
| 03/12/2020 |
8-K
| Quarterly results |
| 11/12/2019 |
8-K
| Quarterly results |
| 08/07/2019 |
8-K
| Quarterly results |
| 05/10/2019 |
8-K
| Quarterly results |
| 03/07/2019 |
8-K
| Quarterly results |
| 11/07/2018 |
8-K
| Quarterly results |
| 08/07/2018 |
8-K
| Quarterly results |
| 05/08/2018 |
8-K
| Quarterly results |
| 03/08/2018 |
8-K
| Quarterly results |
| 11/07/2017 |
8-K
| Quarterly results|
Docs:
|
"Ocular Therapeutix™ Reports Third Quarter 2017 Financial Results and Provides Corporate Update Conference Call Today at 5:00pm Eastern Time BEDFORD, Mass, November 7, 2017 - Ocular Therapeutix™, Inc. , a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye, today announced financial results for the third quarter ended September 30, 2017, and provided a corporate update. “In addition to refining our manufacturing process for DEXTENZA™, we are also working diligently on a continuous improvement plan that will bring our manufacturing unit into compliance with GMP standards. We believe the completion of this work is essential for the timely resubmission of the DEXTENZA™ New Drug Application, as ..." |
|
| 08/08/2017 |
8-K
| Quarterly results|
Docs:
|
"Ocular Therapeutix™ Reports Second Quarter 2017 Financial Results and Provides Corporate Update Conference Call Today at 5:00pm Eastern Time BEDFORD, Mass, August 8, 2017 - Ocular Therapeutix™, Inc. , a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye, today announced financial results for the second quarter ended June 30, 2017, and provided a corporate update. “This is an important time for Ocular Therapeutix as we focus our efforts on the resubmission of our NDA for DEXTENZA™ for the treatment of post-surgical ocular pain while continuing to advance our pipeline programs,” said Antony Mattessich, Chief Executive Officer. “My goal as CEO is to fully realize the opportunities for Ocular ..." |
|
| 03/10/2017 |
8-K
| Form 8-K - Current report |
| 11/09/2016 |
8-K
| Form 8-K - Current report |
| 08/09/2016 |
8-K
| Quarterly results |
| 05/10/2016 |
8-K
| Form 8-K - Current report |
| 03/10/2016 |
8-K
| Form 8-K - Current report |
| 11/10/2015 |
8-K
| Quarterly results |
| 08/10/2015 |
8-K
| Quarterly results |
| 05/15/2015 |
8-K
| Quarterly results |
| 03/10/2015 |
8-K
| Quarterly results |
| 11/12/2014 |
8-K
| Quarterly results |
|
|